LMWH to prevent placenta-mediated pregnancy complications: An update

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 619-638

  Duffett, Lisa ^a   Rodger, Marc ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Antithrombotic treatment; Heparin; Placenta complications; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; PROGESTERONE; ANTICOAGULANT AGENT;

ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; BIRTH RATE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FETUS DEATH; GENE MUTATION; HIGH RISK PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLACENTA DISORDER; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT ABORTION; REVIEW; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; THROMBOPHILIA; TREATMENT DURATION; BLOOD CLOTTING; DRUG EFFECTS; FEMALE; MORTALITY; PLACENTA DISEASES; PREGNANCY; RECURRENT DISEASE; RISK FACTOR;

ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLACENTA DISEASES; PREGNANCY; RECURRENCE; RISK FACTORS;

EID: 84922918134     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13209     Document Type: Review

References (93)

1. Abou-Nassar, K., Carrier, M., Ramsay, T. & Rodger, M.A. (2011) The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thrombosis Research, 128, 77-85.
2. ACOG Committee on Practice Bulletins (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. International Journal of Gynecology & Obstetrics, 77, 67-75.
3. Ananth, C.V., Berkowitz, G.S., Savitz, D.A. & Lapinski, R.H. (1999) Placental abruption and adverse perinatal outcomes. Journal of the American Medical Association, 282, 1646-1651.
4. Ananth, C.V., Peltier, M.R., Chavez, M.R., Kirby, R.S., Getahun, D. & Vintzileos, A.M. (2007) Recurrence of ischemic placental disease. Obstetrics and Gynecology, 110, 128-133.
5. Andreoli, L., Chighizola, C.B., Banzato, A., Pons-Estel, G.J., de Ramire, J.G. & Erkan, D. (2013) Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care & Research, 65, 1869-1873.
6. Avagliano, L., Bulfamante, G.P., Morabito, A. & Marconi, A.M. (2011) Abnormal spiral artery remodelling in the decidual segment during pregnancy: from histology to clinical correlation. Journal of Clinical Pathology, 64, 1064-1068.
7. Badawy, A.M., Khiary, M., Sherif, L.S., Hassan, M., Ragab, A. & Abdelall, I. (2008) Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. Journal of Obstetrics and Gynaecology, 28, 280-284.
8. Bates, S.M., Greer, I.A., Middeldorp, S., Veenstra, D.L., Prabulos, A.M. & Vandvik, P.O. (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e691S-e736S.
9. Bennett, S.A., Bagot, C.N. & Arya, R. (2012) Pregnancy loss and thrombophilia: the elusive link. British Journal of Haematology, 157, 529-542.
10. Bouvier, S., Cochery-Nouvellon, E., Lavigne-Lissalde, G., Mercier, E., Fabbro-Peray, P., Balducchi, J.P., Mares, P. & Gris, J.C. (2014) Comparative incidence of pregnancy outcomes in thrombophilia-positive women from the NOH-APS observational study. Blood, 123, 414-421.
11. Brigham, S.A., Conlon, C. & Farquharson, R.G. (1999) A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Human Reproduction, 14, 2868-2871.
12. Carberry, A.E., Gordon, A., Bond, D.M., Hyett, J., Raynes-Greenow, C.H. & Jeffery, H.E. (2014) Customised versus population-based growth charts as a screening tool for detecting small for gestational age infants in low-risk pregnant women. The Cochrane Database of Systematic Reviews, (5), CD008549.
13. Christiansen, D.M., Elklit, A. & Olff, M. (2013) Parents bereaved by infant death: PTSD symptoms up to 18 years after the loss. General Hospital Psychiatry, 35, 605-611.
14. Clark, P., Greer, I.A. & Walker, I.D. (1999) Interaction of the protein C/protein S anticoagulant system, the endothelium and pregnancy. Blood Reviews, 13, 127-146.
15. Clark, P., Walker, I.D., Langhorne, P., Crichton, L., Thomson, A., Greaves, M., Whyte, S. & Greer, I.A. (2010) SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood, 115, 4162-4167.
16. Clausson, B., Gardosi, J., Francis, A. & Cnattingius, S. (2001) Perinatal outcome in SGA births defined by customised versus population-based birthweight standards. British Journal of Obstetrics and Gynaecology, 108, 830-834.
17. Clifford, K., Rai, R. & Regan, L. (1997) Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Human Reproduction, 12, 387-389.
18. von Dadelszen, P., Magee, L.A. & Roberts, J.M. (2003) Subclassification of preeclampsia. Hypertension in Pregnancy, 22, 143-148.
19. Dao, V. & Rodger, M. (2009) Anticoagulants to prevent placenta-mediated pregnancy complications: a review of current evidence. Current Opinion in Hematology, 16, 386-390.
20. Dekker, G. (2005) Prothrombotic mechanisms in preeclampsia. Thrombosis Research, 115, 17-21.
21. Dendrinos, S., Sakkas, E. & Makrakis, E. (2009) Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. International Journal of Gynecology & Obstetrics, 104, 223-225.
22. D'Ippolito, S., Ortiz, A.S., Veglia, M., Tersigni, C. & Di, S.N. (2011) Low molecular weight heparin in obstetric care: a review of the literature. Reproductive Sciences, 18, 602-613.
23. Dodd, J.M., McLeod, A., Windrim, R.C. & Kingdom, J. (2013) Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. The Cochrane Database of Systematic Reviews, (7), CD006780.
24. Dolitzky, M., Inbal, A., Segal, Y., Weiss, A., Brenner, B. & Carp, H. (2006) A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertility and Sterility, 86, 362-366.
25. Dudding, T.E. & Attia, J. (2004) The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thrombosis and Haemostasis, 91, 700-711.
26. Duley, L., Henderson-Smart, D.J., Meher, S. & King, J.F. (2007) Antiplatelet agents for preventing pre-eclampsia and its complications. The Cochrane Database of Systematic Reviews, 2, CD004659.
27. Farquharson, R.G., Quenby, S. & Greaves, M. (2002) Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics and Gynecology, 100, 408-413.
28. Fawzy, M., Shokeir, T., El-Tatongy, M., Warda, O., El-Refaiey, A.A. & Mosbah, A. (2008) Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Archives of Gynecology and Obstetrics, 278, 33-38.
29. Fouda, U.M., Sayed, A.M., Abdou, A.M., Ramadan, D.I., Fouda, I.M. & Zaki, M.M. (2011) Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. International Journal of Gynecology & Obstetrics, 112, 211-215.
30. Franklin, R.D. & Kutteh, W.H. (2002) Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Human Reproduction, 17, 2981-2985.
31. Goel, N., Tuli, A. & Choudhry, R. (2006) The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Medical Science Monitor, 12, CR132-CR136.
32. Greer, I.A. (2009) Low molecular weight heparin for pregnancy complications? Thrombosis Research, 123, S22-S25.
33. Greer, I.A., Brenner, B. & Gris, J.C. (2014) Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? British Journal of Haematology, 165, 585-599.
34. Gris, J.C., Ripart-Neveu, S., Maugard, C., Tailland, M.L., Brun, S., Courtieu, C., Biron, C., Hoffet, M., Hedon, B. & Mares, P. (1997) Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thrombosis and Haemostasis, 77, 1096-1103.
35. Gris, J.C., Quere, I., Monpeyroux, F., Mercier, E., Ripart-Neveu, S., Tailland, M.L., Hoffet, M., Berlan, J., Daures, J.P. & Mares, P. (1999) Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent-the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thrombosis and Haemostasis, 81, 891-899.
36. Gris, J.C., Lissalde-Lavigne, G., Quere, I., Dauzat, M. & Mares, P. (2006) Prophylaxis and treatment of thrombophilia in pregnancy. Current Opinion in Hematology, 13, 376-381.
37. Gris, J.C., Chauleur, C., Faillie, J.L., Baer, G., Mares, P., Fabbro-Peray, P., Quere, I., Lefrant, J.Y., Haddad, B. & Dauzat, M. (2010) Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thrombosis and Haemostasis, 104, 771-779.
38. Gris, J.C., Chauleur, C., Molinari, N., Mares, P., Fabbro-Peray, P., Quere, I., Lefrant, J.Y., Haddad, B. & Dauzat, M. (2011) Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thrombosis and Haemostasis, 106, 1053-1061.
39. Hossain, N. & Paidas, M.J. (2007) Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Seminars in Perinatology, 31, 208-212.
40. Howley, H.E., Walker, M. & Rodger, M.A. (2005) A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. American Journal of Obstetrics and Gynecology, 192, 694-708.
41. Huppertz, B. (2011) Placental pathology in pregnancy complications. Thrombosis Research, 127, S96-S99.
42. Jaslow, C.R., Carney, J.L. & Kutteh, W.H. (2010) Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertility and Sterility, 93, 1234-1243.
43. de Jesus, G.R., Agmon-Levin, N., Andrade, C.A., Andreoli, L., Chighizola, C.B., Porter, T.F., Salmon, J., Silver, R.M., Tincani, A. & Branch, D.W. (2014) 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmunity Reviews, 13, 795-813.
44. de Jong, P.G., Kaandorp, S., Di, N.M., Goddijn, M. & Middeldorp, S. (2014) Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. The Cochrane Database of Systematic Reviews, (7), CD004734.
45. Kaandorp, S.P., Goddijn, M., van der Post, J.A., Hutten, B.A., Verhoeve, H.R., Hamulyak, K., Mol, B.W., Folkeringa, N., Nahuis, M., Papatsonis, D.N., Buller, H.R., vand, V. & Middeldorp, S. (2010) Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. New England Journal of Medicine, 362, 1586-1596.
46. Keeling, D., Mackie, I., Moore, G.W., Greer, I.A. & Greaves, M. (2012) Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 157, 47-58.
47. Khong, Y. & Brosens, I. (2011) Defective deep placentation. Best Practice & Research. Clinical Obstetrics & Gynaecology, 25, 301-311.
48. Kingdom, J.C. & Drewlo, S. (2011) Is heparin a placental anticoagulant in high-risk pregnancies? Blood, 118, 4780-4788.
49. Kingdom, J.C., Walker, M., Proctor, L.K., Keating, S., Shah, P.S., McLeod, A., Keunen, J., Windrim, R.C. & Dodd, J.M. (2011) Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. Journal of Thrombosis and Haemostasis, 9, 1483-1492.
50. Kovalevsky, G., Gracia, C.R., Berlin, J.A., Sammel, M.D. & Barnhart, K.T. (2004) Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Archives of Internal Medicine, 164, 558-563.
51. Kujovich, J.L. (2004) Thrombophilia and pregnancy complications. American Journal of Obstetrics and Gynecology, 191, 412-424.
52. Kupferminc, M., Rimon, E., Many, A., Maslovitz, S., Lessing, J.B. & Gamzu, R. (2011) Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagulation & Fibrinolysis, 22, 123-126.
53. Kutteh, W.H. (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology, 174, 1584-1589.
54. Laskin, C.A., Spitzer, K.A., Clark, C.A., Crowther, M.R., Ginsberg, J.S., Hawker, G.A., Kingdom, J.C., Barrett, J. & Gent, M. (2009) Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. The Journal of Rheumatology, 36, 279-287.
55. Lausman, A., McCarthy, F.P., Walker, M. & Kingdom, J. (2012) Screening, diagnosis, and management of intrauterine growth restriction. Journal of Obstetrics and Gynaecology Canada, 34, 17-28.
56. Lausman, A., Kingdom, J., Gagnon, R., Basso, M., Bos, H., Crane, J., Davies, G., Delisle, M.F., Hudon, L., Menticoglou, S., Mundle, W., Ouellet, A., Pressey, T., Pylypjuk, C., Roggensack, A. & Sanderson, F. (2013) Intrauterine growth restriction: screening, diagnosis, and management. Journal of Obstetrics and Gynaecology Canada, 35, 741-757.
57. Lykke, J.A., Bare, L.A., Olsen, J., Lagier, R., Arellano, A.R., Tong, C., Paidas, M.J. & Langhoff-Roos, J. (2012) Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. Journal of Thrombosis and Haemostasis, 10, 1320-1325.
58. Lynch, A., Marlar, R., Murphy, J., Davila, G., Santos, M., Rutledge, J. & Emlen, W. (1994) Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Annals of Internal Medicine, 120, 470-475.
59. Magee, L.A., Pels, A., Helewa, M., Rey, E. & von, D.P. (2014) Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. Journal of Obstetrics and Gynaecology Canada, 36, 416-438.
60. Mak, A., Cheung, M.W., Cheak, A.A. & Ho, R.C. (2010) Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology, 49, 281-288.
61. Martinelli, I., Ruggenenti, P., Cetin, I., Pardi, G., Perna, A., Vergani, P., Acaia, B., Facchinetti, F., La Sala, G.B., Bozzo, M., Rampello, S., Marozio, L., Diadei, O., Gherardi, G., Carminati, S., Remuzzi, G. & Mannucci, P.M. (2012) Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood, 119, 3269-3275.
62. Mello, G., Parretti, E., Fatini, C., Riviello, C., Gensini, F., Marchionni, M., Scarselli, G.F., Gensini, G.F. & Abbate, R. (2005) Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension, 45, 86-91.
63. Middeldorp, S. (2011) Is thrombophilia testing useful? The Education Program of the American Society of Hematology, 2011, 150-155.
64. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derksen, R.H., DE Groot, P.G., Koike, T., Meroni, P.L., Reber, G., Shoenfeld, Y., Tincani, A., Vlachoyiannopoulos, P.G. & Krilis, S.A. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295-306.
65. Noble, L.S., Kutteh, W.H., Lashey, N., Franklin, R.D. & Herrada, J. (2005) Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertility and Sterility, 83, 684-690.
66. Norwitz, E.R. (2007) Defective implantation and placentation: laying the blueprint for pregnancy complications. Reproductive Biomedicine Online, 14 Spec No 1, 101-109.
67. Opatrny, L., David, M., Kahn, S.R., Shrier, I. & Rey, E. (2006) Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. The Journal of Rheumatology, 33, 2214-2221.
68. Oyelese, Y. & Ananth, C.V. (2006) Placental abruption. Obstetrics and Gynecology, 108, 1005-1016.
69. Pallotto, E.K. & Kilbride, H.W. (2006) Perinatal outcome and later implications of intrauterine growth restriction. Clinical Obstetrics and Gynecology, 49, 257-269.
70. do Prado, A.D., Piovesan, D.M., Staub, H.L. & Horta, B.L. (2010) Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstetrics and Gynecology, 116, 1433-1443.
71. Rai, R. & Regan, L. (2006) Recurrent miscarriage. Lancet, 368, 601-611.
72. Rai, R.S., Clifford, K., Cohen, H. & Regan, L. (1995) High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Human Reproduction, 10, 3301-3304.
73. Rai, R., Cohen, H., Dave, M. & Regan, L. (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal, 314, 253-257.
74. Regan, L. & Rai, R. (2000) Epidemiology and the medical causes of miscarriage. Baillière's Best Practice & Research. Clinical Obstetrics & Gynaecology, 14, 839-854.
75. Rey, E., Kahn, S.R., David, M. & Shrier, I. (2003) Thrombophilic disorders and fetal loss: a meta-analysis. Lancet, 361, 901-908.
76. Rey, E., Garneau, P., David, M., Gauthier, R., Leduc, L., Michon, N., Morin, F., Demers, C., Kahn, S.R., Magee, L.A. & Rodger, M. (2009) Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis, 7, 58-64.
77. van Rijn, B.B., Hoeks, L.B., Bots, M.L., Franx, A. & Bruinse, H.W. (2006) Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. American Journal of Obstetrics and Gynecology, 195, 723-728.
78. Robertson, L., Wu, O., Langhorne, P., Twaddle, S., Clark, P., Lowe, G.D., Walker, I.D., Greaves, M., Brenkel, I., Regan, L. & Greer, I.A. (2006) Thrombophilia in pregnancy: a systematic review. British Journal of Haematology, 132, 171-196.
79. Rodger, M.A. (2011) Anticoagulant prophylaxis for placenta mediated pregnancy complications. Thrombosis Research, 127, S76-S80.
80. Rodger, M.A., Betancourt, M.T., Clark, P., Lindqvist, P.G., Dizon-Townson, D., Said, J., Seligsohn, U., Carrier, M., Salomon, O. & Greer, I.A. (2010) The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Medicine, 7, e1000292.
81. Rodger, M.A., Walker, M.C., Smith, G.N., Wells, P.S., Ramsay, T., Langlois, N.J., Carson, N., Carrier, M., Rennicks, W.R., Shachkina, S. & Wen, S.W. (2014a) Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. Journal of Thrombosis and Haemostasis, 12, 469-478.
82. Rodger, M., Hague, W., Kingdom, J., Kahn, S., Karovitch, A., Sermer, M., Clement, A.M., Coat, S., Chan, W.S., Said, J., Rey, E., Robinson, S., Khurana, R., Demers, C., Kovacs, M.J., Solymoss, S., Hinshaw, K., Dwyer, J., Smith, G., McDonald, S., Newstead-Angel, J., McLeod, A., Khandelwal, M., Silver, R.M., Le Gal, G., Greer, I., Keely, E., Rosene-Montella, K., Walker, M., Wells, P.S. & for the TIPPS Investigators (2014b) Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. The Lancet, doi: 10.1016/S0140-6736(14)60793-5 [Epub ahead of print].
83. Rodger, M.A., Carrier, M., Le Gal, G., Martinelli, I., Perna, A., Rey, E., de Vries, J.I. & Gris, J.C. (2014c) Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood, 123, 822-828.
84. Romero, R., Kusanovic, J.P., Chaiworapongsa, T. & Hassan, S.S. (2011) Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Practice & Research. Clinical Obstetrics & Gynaecology, 25, 313-327.
85. Simchen, M.J., Dulitzki, M., Rofe, G., Shani, H., Langevitz, P., Schiff, E. & Pauzner, R. (2011) High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstetricia et Gynecologica Scandinavica, 90, 1428-1433.
86. Stephenson, M.D., Ballem, P.J., Tsang, P., Purkiss, S., Ensworth, S., Houlihan, E. & Ensom, M.H. (2004) Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Journal of Obstetrics and Gynaecology Canada, 26, 729-734.
87. Tikkanen, M. (2011) Placental abruption: epidemiology, risk factors and consequences. Acta Obstetricia et Gynecologica Scandinavica, 90, 140-149.
88. Tikkanen, M., Luukkaala, T., Gissler, M., Ritvanen, A., Ylikorkala, O., Paavonen, J., Nuutila, M., Andersson, S. & Metsaranta, M. (2013) Decreasing perinatal mortality in placental abruption. Acta Obstetricia et Gynecologica Scandinavica, 92, 298-305.
89. Triolo, G., Ferrante, A., Ciccia, F., Accardo-Palumbo, A., Perino, A., Castelli, A., Giarratano, A. & Licata, G. (2003) Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis and Rheumatism, 48, 728-731.
90. Visser, J., Ulander, V.M., Helmerhorst, F.M., Lampinen, K., Morin-Papunen, L., Bloemenkamp, K.W. & Kaaja, R.J. (2011) Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thrombosis and Haemostasis, 105, 295-301.
91. de Vries, J.I., van Pampus, M.G., Hague, W.M., Bezemer, P.D. & Joosten, J.H. (2012) Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. Journal of Thrombosis and Haemostasis, 10, 64-72.
92. Wu, O., Robertson, L., Twaddle, S., Lowe, G., Clark, P., Walker, I., Brenkel, I., Greaves, M., Langhorne, P., Regan, L. & Greer, I. (2005) Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. British Journal of Haematology, 131, 80-90.
93. Ziakas, P.D., Pavlou, M. & Voulgarelis, M. (2010) Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstetrics and Gynecology, 115, 1256-1262.